



Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

Intellectual Property

New York Office | +1.212.940.8552

deepro.mukerjee@katten.com

Deepro R. Mukerjee is chair of Katten's global Intellectual Property practice and is a member of both the firm's Executive Committee and Board of Directors. Multi-billion dollar corporations, a major academic institution and some of the largest generic pharmaceutical companies in the world call on Deepro for their respective IP needs – particularly when it comes to complex or high-stakes litigations. Deepro is a first chair litigator, having tried numerous patent trials over his 20-year career. His cases are often featured by media outlets throughout the country.

Intellectual Property Litigation and IP Corporate Transactions

Deepro has been lead trial counsel in dozens of cases, often taking them to trial and subsequent appeals. He is also experienced at managing *inter partes* review proceedings before the Patent Trial and Appeal Board. While he is often noted for his successes in Hatch-Waxman litigations, Deepro's litigation experience is far more expansive and covers matters related to product manufacturing, biotechnology, botanicals, business methods, web-related services and voice recognition software.

A recognized industry leader, Deepro has, among other accolades, been named to the *IAM 1000* leading worldwide patent practitioners list for 10 years in a row and was designated an "IP Star" by *Managing Intellectual Property* for the fifth consecutive year in 2024.

Representative Experience

- Counsel for the implantable medical device business line of a global materials science company.
- Lead trial counsel for some of the world's largest generic pharmaceutical companies in over a dozen currently pending Hatch-Waxman litigations throughout the country.
- Counsel for a multi-billion dollar global provider of blood and plasma supplies and services, including patent portfolio development and strategy.

Practices

- Hatch-Waxman Litigation
- Intellectual Property
- Intellectual Property Litigation
- Patent Litigation and Patents
- Pharmaceutical and Life Sciences Litigation

Industries

- Pharmaceutical and Life Sciences

Education

- JD, Fordham University School of Law
- BS, Fordham University, *summa cum laude*
- BA, University of Oxford

Bar Admissions

- New York

Court Admissions

- US Court of Appeals, Federal Circuit
- US District Court, Southern District of New York
- US District Court, Eastern District of New York
- US Patent & Trademark Office

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- Counsel for an international world leader in voice software, and specifically voice capture for leading organizations across financial, contact center, government and public safety sectors. Served as lead trial counsel in defending against a multi-patent litigation in the Southern District of New York. Successfully invalidated asserted claims at the claim construction stage.
- Counsel for one of the world's largest career service providers linking job seekers to employers and vice versa. Served as lead trial counsel in multiple litigations and routinely handled cross-border transactional IP and corporate matters.
- Counsel for not-for-profit multi-type library consortium on all legal matters, including licensing, contracting, and IP protection.
- Lead trial counsel for premier processor and distributor of amniotic surgical tissue grafts in breach of contract and tortious interference case in the US District Court for the District of Maryland.
- Lead trial counsel for sponsorship-driven, social-media marketer in patent litigation in the US District Court for the Eastern District of Texas. Obtained a stay by petitioning the USPTO to accept a covered business method petition on several of the asserted patents.*

Notable Achievements

- Lead trial counsel in the Northern District of West Virginia involving two patents related to the treatment of severe pulmonary arterial hypertension. Obtained a reversal of an unfavorable claim construction decision before the Federal Circuit and then obtained a trial decision of non-infringement on remand.
- Lead trial counsel in the US District Court for the District of Delaware involving a patent related to chronic lymphocytic leukemia using bendamustine. Obtained non-infringement judgment from the bench before even presenting our invalidity defense. Obtained a Rule 36 affirmance of that judgment on appeal days after oral argument was heard.
- Lead trial counsel in the District of Delaware involving a patent associated with the treatment of the pain of osteoarthritis of the knees. Obtained summary judgment that our client had a license to the asserted patent within six months of the complaint being filed.
- Lead trial counsel defending our client against a suit involving multiple patents associated with pre-colonoscopy cleansing using sodium picosulfate, magnesium oxide and anhydrous citric acid. Obtained judgment of non-infringement on both asserted Orange Book patents and attorneys' fees with respect to a third patent.

Professional & Community Involvement

- American Intellectual Property Law Association
- Law360, Intellectual Property Editorial Board, 2025
- New York Intellectual Property Law Association

“

"Deepro is incredibly gifted and talented when it comes to litigation. He brings a rare kind of advocacy for his clients." "Deepro is a brilliant lawyer and a real pleasure to work with." "He is always responsive and ever-mindful of what really matters. He is polished, articulate, presentable, and extremely likeable."

**Chambers USA 2023
(New York, Intellectual Property:
Patent) survey response**

”

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- Lead trial counsel for Mylan in an infringement dispute regarding multiple patents for topical foam acne treatment Evoclin®. Defendant Glenmark Pharmaceuticals filed antitrust counterclaims in response. Successfully dismissed all such counterclaims.
- Co-counsel in US District Court for New Jersey involving multiple patents directed to a dipeptidyl peptidase-4 inhibitor and its use for treatment of Type II diabetes. Obtained favorable judgment at the district court level followed by an affirmation of invalidity of two patents as lead counsel on appeal.
- Lead trial counsel for one of the world's largest fresh produce distributors in a plant patent litigation in the US District Court for the Southern District of Florida. Obtained an apology from plaintiff for bringing the suit in the first place and a dismissal of all claims brought against our client. Also obtained acknowledgment that our client had an unrestricted right to practice the invention claimed in the plant patent all along.
- Lead trial counsel in US District Court for the District of Delaware involving patent that purports to be related to treatment of deep vein thrombosis using rivaroxaban.
- Lead trial counsel in multiple cases involving patents associated with the treatment of early-stage idiopathic Parkinson's disease and moderate-to-severe restless legs syndrome using rotigotine. Obtained a Federal Circuit affirmation of invalidity of one patent, a grant of partial summary judgment in a follow-on litigation and ultimately settled on favorable terms prior to trial.
- Lead trial counsel for one of the world's largest fresh produce distributors in a breach of contract, trade dress infringement and fraud on a US Patent and Trademark Office case in the US District Court for the Central District of California. Obtained a favorable settlement, with defendant assigning the US Registration and EU Registration for the mark MANGO PRO to our client.
- Lead trial counsel in US District Court for the District of Delaware involving multiple patents associated with treatment of irritable bowel syndrome with constipation, and chronic idiopathic constipation using linaclotide.
- Lead trial counsel in US District Court for the District of Delaware involving multiple patents associated with the treatment of major depressive disorder using vortioxetine hydrobromide.
- Lead trial counsel in US District Court for the District of Delaware involving a patent associated with the treatment of HIV-1 infection in

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

adults and pediatric patients weighing at least 40 kg using dolutegravir or abacavir, dolutegravir and lamivudine.

- Lead trial counsel for leading online provider of employment-related services in patent infringement action in the US District Court for the Southern District of California. Successfully argued a case-dispositive Markman hearing which led to favorable settlement.

*Experience prior to Katten

Recognitions

Recognized or listed in the following:

- *ANDA Litigation Intelligence Report*
 - Best Performing ANDA Attorneys Representing Defendants, 2020-2022; Top 20, 2023; Top 50, 2024; Top 20, 2025
 - Most Active ANDA Attorneys Representing Defendants, Top 100, 2020–2022; Top 3, 2023; Top 10, 2024-2025
 - Best Performing ANDA Attorneys Overall (Representing Plaintiffs or Defendants), 2020–2021, 2023-2025
 - Most Active ANDA Attorneys Overall (Representing Plaintiffs and Defendants); Top 100, 2020–2022; Top 10, 2023; Top 20, 2024-2025
- *BTI Client Service All-Stars*
 - 2020 and 2021
 - 2022, Elite MVP All-Stars
- *Chambers USA*
 - Intellectual Property: Patent, 2022–2025
- *Crain's New York Business*
 - Notable Litigators and Trial Attorneys, 2025
 - Notable Leaders in Accounting, Consulting & Law, 2024
- *Forbes*
 - America's Top Lawyers, 2025
- IAM Patent 1000
 - Silver – Individual: Litigation, New York, 2022–2025
 - Recognized Individual, New York, 2014–2021
- *Managing Intellectual Property*
 - IP Star – Patent, 2019–2025

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- IP Stars Handbook, 2019–2021
- Litigator of the Year, New York – Finalist, 2022, 2024–2025
- *The American Lawyer*
 - Northeast Trailblazer, 2022
- *The Legal 500 United States*
 - Recommended Attorney, 2022, 2024–2025
- Thomson Reuters
 - Stand-out Lawyer, 2026

News

- 13 Katten Attorneys Honored Among *Thomson Reuters* Stand-out Lawyers (February 5, 2026)
- *Forbes* Names Deepro Mukerjee and David Crichlow to "America's Top Lawyers 2025" List (September 16, 2025)
- Katten Earns Repeat Recognition as a Top Three ANDA Litigation Firm (September 2, 2025)
- Katten Receives High Marks in the Legal 500 US 2025 Guide (June 11, 2025)
- *Managing Intellectual Property* Honors Katten and Multiple IP Stars in 2025 Rankings (June 5, 2025)
- *Chambers USA 2025* Ranks Katten as Leading Law Firm (June 5, 2025)
- Katten Recognized as Global Patent Leader in *IAM Patent 1000* (May 29, 2025)
- *Managing Intellectual Property 2025 Americas Awards* Honor Katten and Karen Artz Ash (April 25, 2025)
- Katten Attorneys Named Among *Crain's New York Business 2025* Notable Litigators & Trial Attorneys (April 1, 2025)
- Five Katten Partners Named as Members of *Law360 2025* Editorial Boards (March 28, 2025)
- Katten Lands Intellectual Property Partner Nathan Smith in London (January 20, 2025)
- *Crain's New York Business* Honors Wendy Cohen and Deepro Mukerjee as 2024 Notable Leaders in Law (December 10, 2024)
- Katten Ranked Top Three Firm in ANDA Litigation (September 3, 2024)

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- *Managing Intellectual Property* Honors Katten in 2024 Copyright Rankings (July 31, 2024)
- *Managing Intellectual Property* Recognizes 2024 Katten IP Stars (July 3, 2024)
- Katten Highly Ranked in Legal 500 United States 2024 (June 12, 2024)
- Katten Receives High Marks in *Chambers USA* Guide 2024 (June 6, 2024)
- Katten Named Intellectual Property Leader in *IAM Patent 1000* (June 5, 2024)
- Another Precedent-Setting Remand from the Federal Circuit Garners Media Attention (April 2, 2024)
- Katten's IP Litigation Team Prevails at Trial, Securing Patent Win for Mylan Pharmaceuticals (March 15, 2024)
- Precedent-Setting Patent Win in Federal Circuit Creates Media Buzz From *Bloomberg Law*, *Reuters*, and More (November 7, 2023)
- Katten Ranked Top Three Firm in Hatch-Waxman Litigation (September 5, 2023)
- *Managing Intellectual Property* Recognizes Katten IP Stars (June 29, 2023)
- Katten IP Practice Lauded in *IAM Patent 1000* (June 29, 2023)
- Katten Boosts Rankings in *Chambers USA Guide 2023* (June 1, 2023)
- Fed. Circ. Won't Revive Parkinson's Drug Patent | *Law360* (April 12, 2023)
- Federal Court Awards Precedent-Setting Victory to Katten Client Apotex in Patent Infringement Dispute (November 9, 2022)
- Katten Intellectual Property Team Secures Significant Victory for Apotex in Hatch-Waxman Litigation (November 1, 2022)
- Katten Intellectual Property Group Grows With Advertising Litigator (October 26, 2022)
- *Law.com* Profiles Deepro Mukerjee's Path to Intellectual Property Department Chair (August 25, 2022)
- Katten Ranks Among Top Three Most Active Law Firms in ANDA Litigation (August 22, 2022)
- Katten Lauded in *IAM Patent 1000* 2022 (June 29, 2022)

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- Katten Awarded Top Ranking in Structured Finance: Securitization in The Legal 500 United States 2022 (June 8, 2022)
- Deepro Mukerjee Honored as a 2022 "Northeast Trailblazer" by *The American Lawyer* (June 3, 2022)
- Katten Ranked Leading Law Firm by *Chambers USA 2022* (June 1, 2022)
- *Managing Intellectual Property* Recognizes Seven Katten Attorneys as 2022 IP Stars (May 27, 2022)
- High Court Delays Mulling Apple, Mylan Fintiv Challenges | *Law360* (November 24, 2021)
- [Report: The Best Hatch-Waxman Law Firms of 2021 | IP Watchdog](#) (October 18, 2021)
- Generics Group, Intel Back Mylan's Fintiv Fight At High Court | *Law360* (September 14, 2021)
- Katten Ranked in Top Five Most Active Law Firms for ANDA Litigation (August 23, 2021)
- Katten Appoints New Practice Heads, Building on Stellar Leadership (July 15, 2021)
- Katten Ranked Best in Intellectual Property by *Managing IP Stars 2021* (July 7, 2021)
- Katten Attorneys Named Leaders in Patent Law by *IAM Patent 1000* (July 6, 2021)
- Katten Client Mylan Wins Patent Infringement Case Regarding Parkinson's Drug Treatment (June 11, 2021)
- Deepro Mukerjee Talks to *Law360* on the Federal Circuit Court's Increasing Diversity (April 26, 2021)
- Katten Partners Praised for Outstanding Client Service (December 10, 2020)
- Deepro Mukerjee Talks to *Bloomberg Law* About His IP Practice and How the COVID-19 Pandemic Has Altered Litigation and the Industry (November 20, 2020)
- Katten Named Among Top Three Best Performing Law Firms for ANDA Litigation (August 19, 2020)
- Katten Attorneys Named Leaders in Patent Law by *IAM Patent 1000* (June 22, 2020)
- [Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB](#) (June 2, 2020)

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- [MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent](#) (May 13, 2020)
- Katten Ranked Best in Intellectual Property by Managing IP Stars 2020 (May 1, 2020)
- [Fed. Circ. Revives Boehringer Diabetes Drug Patent](#) (March 16, 2020)
- Katten Intellectual Property Partner Featured in Patent Industry Report (August 29, 2019)
- Katten Attorneys Win Dismissal of Avocado Patent Lawsuit (June 12, 2019)
- Deepro Mukerjee Quoted in *Law360* Regarding Plant Patent Infringement Win (June 11, 2019)
- Katten Attorneys Recognized as 2019 Managing IP Stars (May 30, 2019)
- Katten Draws Top IP Litigation Talent with Broad Pharma Experience (May 7, 2018)
- Noah Heller Comments on Addition of New IP Litigator and 29 Lateral Partners in 2018 (April 18, 2018)

Publications

- Biosimilars Litigation and Client Counseling (March 18, 2025)
- Increased Scrutiny by Federal Trade Commission of Orange Book Listings (October 2024)
- Top Attorneys in ANDA Litigation: A Spotlight on the Best Performers and Most Active of 2024 (September 26, 2024)
- J&J, Generics Spar In Remand On Schizophrenia Drug Patent | *Law360* (August 5, 2024)
- Privacy, Data and Cybersecurity *Quick Clicks* | Issue 5 (May 18, 2023)
- Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Third Edition (July 15, 2022)
- Whether Obviousness Type Double Patenting Can Be Used to Invalidate Patents That Expire Later Because of Patent Term Adjustment (July 12, 2021)
- Don't Fear IP-Antitrust 'Turducken' in Reverse-Payment Cases (November 24, 2020)

Deepro R. Mukerjee

Partner and Chair, Intellectual Property Department

- The Balance Between Obviousness and Written Description — Lessons Learned from Recent Decisions (August 5, 2020)
- California Enacts "Reverse-Payment" Law Aimed at Patent Settlements — An Initial Look ... Assuming It Is Upheld (May 19, 2020)
- Supreme Court Declines To Disturb Pre-AIA Interpretation of "On Sale" Bar (January 25, 2019)

Presentations and Events

- Paragraph IV Disputes (April 29–30, 2025) | *Speaker* | *IP Life Sciences Leaders on the Rise: Wisdom, War Stories, and Pitfalls to Avoid as You Pave your Career Path*
- 20th Annual Paragraph IV Disputes Conference (April 25-26, 2024)
- Paragraph IV Disputes (April 19 – 20, 2023) | *Speaker* | *Track 1 of The Practice of PIV Disputes*
- 17th Annual Paragraph IV Disputes Conference (April 26–27, 2022) | *Speaker* | *The Business of PIV Disputes — Cross-Border Business Considerations in a Hatch-Waxman Scenario: Masterfully Managing Global Litigation*
- 15th Annual Paragraph IV Disputes (April 26–27, 2021) | *Panelist* | *The Economics and Economy of Drug Patents with ACI's Hatch-Waxman Series Advisory Board Members: Optimizing Product Selection, Identifying Targets for Litigation and Monetizing IP Portfolios*
- 14th Annual Paragraph IV Disputes (October 6–7, 2020) | *Panelist* | *In-House Perspectives on The Future of IP Teams and Working with Outside Counsel*